Pramodini Medicare Ltd vs Suraksha Diagnostic Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Pramodini Medicare Ltd is ₹ 108.65 as of 23 Oct 15:30 . The P/E Ratio of Pramodini Medicare Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Suraksha Diagnostic Ltd changed from 42.2 on March 2025 to 36.9 on March 2026 . This represents a CAGR of -6.49% over 2 years The Market Cap of Pramodini Medicare Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Suraksha Diagnostic Ltd changed from ₹ 1342 crore on March 2025 to ₹ 1187 crore on March 2026 . This represents a CAGR of -5.95% over 2 years The revenue of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 88.73 crore as compare to the Mar '26 revenue of ₹ 82.2 crore. This represent the growth of 7.94% The ebitda of Pramodini Medicare Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Suraksha Diagnostic Ltd for the Jun '26 is ₹ 31.53 crore as compare to the Mar '26 ebitda of ₹ 25.15 crore. This represent the growth of 25.37% The net profit of Pramodini Medicare Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Suraksha Diagnostic Ltd changed from ₹ 7.67 crore to ₹ 12.85 crore over 9 quarters. This represents a CAGR of 25.78% The Dividend Payout of Pramodini Medicare Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Suraksha Diagnostic Ltd changed from 0.76 % on March 2026 to 0.76 % on March 2026 . This represents a CAGR of 0.00% over 1 years .

About Pramodini Medicare Ltd

Pramodini Medicare Limited was originally incorporated on September 12, 2000 as 'Pramodini Medicare Private Limited' with the Registrar of Companies, Andhra Pradesh.
Thereafter, the status of the Company changed to public limited Company and the name was changed to 'Pramodini Medicare Limited' vide fresh certificate of incorporation dated November 12, 2025. Company was originally incorporated in the year 2000 with the objective to provide diagnostic services.
The Company provide a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. Diagnostic services include a comprehensive range of offerings: (i) 'Radiology' which covers Magnetic Resonance Imaging (MRI), Computed Tomography (CT scan), X- ray, Ultrasound with colour doppler, Mammography, DEXA Scan and Intervention Radiology, (ii) 'Clinical Laboratory' which includes Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry and (iii) 'Nuclear Medicine' which includes PET-CT (Positron Emission Tomography-Computed Tomography), SPECT (Single Photon Emission Computed Tomography) and Nuclear therapy.

About Suraksha Diagnostic Ltd

Suraksha Diagnostic Limited was incorporated as Suraksha Diagnostic Private Limited' as a private limited company dated March 15, 2005, issued by the Deputy Registrar of Companies, West Bengal at Kolkata.
Subsequently, Company was converted into a public limited company and the name of Company was changed to Suraksha Diagnostic Limited', and a fresh certificate of incorporation dated July 16, 2024, was issued by the Registrar of Companies, Central Processing Centre. The Company is mainly engaged in running diagnostic centres for carrying out various pathological and radiological testing and medical consultation services in in East India.
In addition to integrated pathology and radiology testing services, it also offer omnichannel medical consultation services via online and offline modes to customers through 43 of its diagnostic centres which house 120 polyclinic chambers hosting 750+ doctors.

FAQs for the comparison of null and Suraksha Diagnostic Ltd

Which company has a larger market capitalization, Pramodini Medicare Ltd or Suraksha Diagnostic Ltd?

Market cap of Pramodini Medicare Ltd is 239 Cr while Market cap of Suraksha Diagnostic Ltd is 1,556 Cr

What are the key factors driving the stock performance of Pramodini Medicare Ltd and Suraksha Diagnostic Ltd?

The stock performance of Pramodini Medicare Ltd and Suraksha Diagnostic Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pramodini Medicare Ltd and Suraksha Diagnostic Ltd?

As of October 25, 2026, the Pramodini Medicare Ltd stock price is INR ₹108.65. On the other hand, Suraksha Diagnostic Ltd stock price is INR ₹298.9.

How do dividend payouts of Pramodini Medicare Ltd and Suraksha Diagnostic Ltd compare?

To compare the dividend payouts of Pramodini Medicare Ltd and Suraksha Diagnostic Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.